Is avonex for ms?

Is Avonex used for multiple sclerosis?

Avonex is approved to treat relapsing forms of multiple sclerosis in adults. It belongs to the interferon beta class of drugs and works by modulating the immune system to reduce inflammation in the brain and spinal cord.

Why do patients choose Avonex over other interferons?

Patients and physicians select Avonex because it requires only one intramuscular injection per week, making it less burdensome than some competing interferon regimens that need more frequent shots. Clinical data show it cuts relapse rates by about one-third compared with placebo in the pivotal trials.

What happens if a patient stops taking Avonex?

Stopping treatment abruptly can allow disease activity to rebound, with some patients seeing higher relapse rates and new MRI lesions in the months after discontinuation. Clinical guidelines generally recommend continuing therapy unless clear reasons justify switching or stopping.

When does the Avonex patent expire?

The primary composition-of-matter patent for interferon beta-1a has already expired, but secondary patents covering formulations and delivery methods still protect the brand product into the 2020s.

Who makes Avonex?

Biogen manufactures and sells Avonex. The company maintains a patient-support program that includes financial assistance options for eligible individuals under commercial insurance.

Can biosimilars enter the market before patent expiry?

Biosimilars for Avonex cannot launch until the remaining formulation patents expire or are successfully challenged in court. Current forecasts show possible entry only after 2025 in some jurisdictions.